TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: An additional phase II study queried a more heterogeneous PTCL population, notably including a subset of patients (17%) with absent CD30 expression based on immunohistochemistry (PTCL-NOS: n = 21, AITL: n = 13).